Loading organizations...
MiMARK is a technology company.
MiMARK develops innovative in vitro diagnostic solutions for improved gynecological disease management, with an initial focus on Endometrial Cancer. Its flagship product, WomEC, is an immunoassay that quantifies specific protein biomarkers present in uterine fluid. This advanced method provides a highly accurate, less invasive diagnostic alternative to traditional cellular analysis, striving for 97% sensitivity and negative predictive value.
Co-founded by Marina Rigau (CEO), Eva Colás (CSO), and Antonio Gil (CMO), MiMARK originated in 2021 as a spin-off from the Vall d'Hebron Institute of Research (VHIR). The founders shared a collective insight into the significant potential of gynecological fluid as a novel, less invasive source for liquid biopsy diagnostics in women's health.
MiMARK's solutions primarily benefit post-menopausal women experiencing abnormal uterine bleeding, offering patients reduced invasiveness and faster diagnoses, and providing doctors with more accurate and objective results. The company's vision centers on reshaping gynecological diagnostics by continuously advancing its portfolio of fluid-based tools, aiming to improve patient management and optimize healthcare system costs.
MiMARK has raised $4.6M across 1 funding round.
MiMARK has raised $4.6M in total across 1 funding round.
MiMARK has raised $4.6M in total across 1 funding round.
MiMARK's investors include Canterbury Scientific, CDTI, Clave Capital, EIC Fund, Inveready, Namarel Ventures, Nara Capital, WA4STEAM.
Direct answer: MiMARK (often styled MiMARK or Mimark) is a women’s‑health medtech startup out of Barcelona building non‑invasive in‑vitro diagnostic tests based on uterine/gynecological liquid biopsies — its lead product targets earlier, more accurate detection of endometrial cancer and the company is transitioning from academic spin‑out into clinical/regulatory validation and commercialization[1][2][4].
High‑level overview
For portfolio / company specifics
Origin story
Core differentiators
Role in the broader tech/health landscape
Quick take & future outlook
Sources and confidence notes
MiMARK has raised $4.6M across 1 funding round. Most recently, it raised $4.6M Seed in November 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 27, 2023 | $4.6M Seed | Canterbury Scientific, CDTI, Clave Capital, EIC Fund, Inveready, Namarel Ventures, Nara Capital, WA4STEAM |